ENTITY
Sino Biopharmaceutical

Sino Biopharmaceutical (1177 HK)

284
Analysis
Health CareHong Kong
Sino Biopharmaceutical Limited, through its subsidiaries, researches, develops, produces, and sells biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis.
more
03 Jun 2019 04:21

Hansoh Pharma IPO: Valuation Reasonable for the Trade-Offs

Hansoh Pharmaceutical (3692 HK) claims to be one of the few R&D driven Chinese pharmaceutical companies. It announced its IPO price range of...

Logo
830 Views
Share
30 May 2019 16:38

Hansoh Pharma (翰森制药) IPO: Strong Cornerstone Line-Up, Upside at Low End

Hansoh Pharma, the largest pharmaceutical listing in Hong Kong this year, launched its book building today. In our previous insights (links...

Logo
985 Views
Share
23 May 2019 09:44

Hansoh Pharma (翰森制药) IPO: Thoughts on Valuation

Hansoh Pharma has started pre-marketing its IPO to raise USD 1bn in its IPO. In our previous insights, we covered the company's major products and...

Logo
894 Views
Share
20 May 2019 18:49

Hansoh Pharma IPO: Growth at the Cost of More Pre-IPO Dividends

Hansoh Pharmaceutical (HANSOH HK) claims to be one of the few R&D driven Chinese pharmaceutical companies. According to press reports, Hansoh...

Logo
693 Views
Share
12 Feb 2019 07:34

Hansoh Pharma IPO Preview: A Decent Story Tarnished by a Huge Pre-IPO Dividend

Hansoh Pharmaceutical (HANSOH HK) claims to be one of the few R&D driven Chinese pharmaceutical companies. According to press reports, Hansoh...

Logo
695 Views
Share
x